Portal de recerca
- Inici
- Projectes i Estudis Clínics
- Estudio aleatorizado, doble ciego, multicéntrico internacional, de fase III para evaluar la eficacia antitumoral y la seguridad de HLX10 (inyección de anticuerpos monoclonales humanizados anti-PD-1 recombinantes) o placebo, en combinación con quimioterapia (carboplatino/cisplatinoetopósido) y radioterapia concomitante en pacientes con cáncer de pulmón de células pequeñas en estadio limitado (CPCP-EL).
Estudio aleatorizado, doble ciego, multicéntrico internacional, de fase III para evaluar la eficacia antitumoral y la seguridad de HLX10 (inyección de anticuerpos monoclonales humanizados anti-PD-1 recombinantes) o placebo, en combinación con quimioterapia (carboplatino/cisplatinoetopósido) y radioterapia concomitante en pacientes con cáncer de pulmón de células pequeñas en estadio limitado (CPCP-EL).
Dades bàsiques
- Protocol:
- HLX10-020-SCLC302
- EURDRACT:
- 2022-002226-27
- NCT:
- Centre:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Any inici:
- 2024
- Any de finalització:
Documents
- No hi ha documents
Grups d'Investigació
Finançadors - Promotors
Resultats de l'Assaig Clínic
[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence
Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda
Editorial Material. 10.1016/j.farma.2024.08.009. 2024
[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Andrés JLP, Solsona MDE
Article. 10.1016/j.farma.2023.10.004. 2024
[Translated article] New challenges in advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2024.05.001. 2024
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.
Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.12.007. 2025
[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.09.006. 2024
A Gadolinium(III) Complex Based on Pyridoxine Molecule with Single-Ion Magnet and Magnetic Resonance Imaging Properties.
Orts-Arroyo, Marta; (...); Martinez-Lillo, Jose
Article. 10.3390/ijms25042112. 2024
A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05).
Conde-Moreno, Antonio J; (...); Ferrer, Carlos
Article. 10.1016/j.prro.2024.04.022. 2024
A randomised trial of short- vs long-term androgen deprivation with salvage radiotherapy for biochemical failure following radical prostatectomy: URONCOR 06-24.
González-San Segundo C; (...); Couñago F
Article. 10.1111/bju.16484. 2024
A Smart Digital Health Platform to Enable Monitoring of Quality of Life and Frailty in Older Patients with Cancer: A Mixed-Methods, Feasibility Study Protocol.
Papachristou, Nikolaos; (...); Bamidis, Panagiotis D.
Article. 10.1016/j.soncn.2023.151437. 2023
Ability of antigen carbohydrate 125 for diagnosis of heart failure with preserved ejection fraction
De Juan Baguda, J. Javier; (...); Delgado Jimenez, J. F.
Meeting Abstract. 2024
Acute performance of stylet driven leads for left bundle branch area pacing: A comparison with lumenless leads
Cano, Oscar; (...); Batul, Syeda Atiqa
Article. 10.1016/j.hroo.2023.11.014. 2023
Alterations in Mitochondrial Oxidative Phosphorylation System: Relationship of Complex V and Cardiac Dysfunction in Human Heart Failure
Gimenez-Escamilla, Isaac; (...); Rosello-Lleti, Esther
Article. 10.3390/antiox13030285. 2024
Altered MicroRNA Maturation in Ischemic Hearts: Implication of Hypoxia on XPO5 and DICER1 Dysregulation and RedoximiR State.
Perez-Carrillo, Lorena; (...); Rosello-Lleti, Esther
Article. 10.3390/antiox12071337. 2023
Alveolar capillary dysplasia with misalignment of the pulmonary veins: A surgical lung biopsy and autopsy in a full-term newborn.
Rodríguez García C; (...); Mancheño Franch N
Article. 10.1016/j.patol.2024.06.005. 2024
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Passaro, A; (...); Cho, B C
Article. 10.1016/j.annonc.2023.10.117. 2024
Analysis of complications in patients with ECMO as a bridge to transplantation since the beginning of the technique (2007-2023)
Guerrero Cervera, Borja; (...); Almenar Bonet, Luis
Meeting Abstract. 2024
Annual evolution of the prescription of drugs with prognostic implications in acute decompensated heart failure with reduced ejection fraction.
López-Vilella R; (...); Almenar Bonet L
Article. 10.1186/s12872-024-03728-y. 2024
Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).
Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ
Letter. 10.1111/jdv.19432. 2023
CA125: a new biomarker in patients with Fontan circulation (vol 76, pg 112, 2023)
Fuentes, Francisco Buendia; (...); Soriano, Joaquin Rueda
Correction. 10.1016/j.rec.2023.03.018. 2023
Capmatinib vs docetaxel as second- or third-line (2/3L) therapy in patients (pts) with METex14-mutated advanced NSCLC (aNSCLC): The GeoMETry-III trial
Vidal, O. J. Juan; (...); Wolf, J.
Meeting Abstract. 10.1016/j.annonc.2023.09.2424. 2023
Circulating long non-coding RNAs detection after heart transplantation and its accuracy in the diagnosis of acute cardiac rejection.
Pérez-Carrillo L; (...); Roselló-Lletí E
Letter. 10.1186/s40364-024-00590-0. 2024
Clinical phenotypes according to diuretic combination in acute heart failure.
Lopez-Vilella, Raquel; (...); Bonet, Luis Almenar
Article. 10.1016/j.hjc.2023.03.009. 2023
Clinical profiling of patients admitted with acute heart failure: a comprehensive survival analysis.
Lopez-Vilella, Raquel; (...); Almenar Bonet, Luis
Article. 10.3389/fcvm.2024.1381514. 2024
Clinical, echocardiographic and analytical patterns of biomarkers in cardiac amyloidosis; a real-world analysis.
Lopez Vilella, R. Raquel; (...); Almenar Bonet, L.
Meeting Abstract. 2024
Combining Serum miR-144-3p and miR-652-3p as Potential Biomarkers for the Early Diagnosis and Stratification of Acute Cellular Rejection in Heart Transplantation Patients.
Pérez-Carrillo L; (...); Roselló-Lletí E
Article. 10.1097/TP.0000000000004622. 2023
Comparative Temporal Analysis of Morbidity and Early Mortality in Heart Transplantation with Extracorporeal Membrane Oxygenation Support: Exploring Trends over Time
Lopez-Vilella, Raquel; (...); Bonet, Luis Almenar
Article. 10.3390/biomedicines12092109. 2024
Comprehensive survival analysis in acute heart failure: profiling patients through clinical examination at admission
Raquel Lopez Vilella, R.; (...); Almenar Bonet, L.
Meeting Abstract. 2024
Conduction System Pacing for Cardiac Resynchronization Therapy
Cano, Oscar; (...); Martinez-Dolz, Luis
Review. 10.3390/jcdd10110448. 2023
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano JB; (...); Soto-Ortega I
Article. 10.1016/j.farma.2023.01.003. 2023
Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.
Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada
Article. 10.1016/j.farma.2023.04.002. 2023
Correction to: Radiation therapy for vulvar cancer: consensus guidelines of the GINECOR working group of the Spanish Society of Radiation Oncology. Part 1: clinical recommendations.
Cordoba Largo S; (...); Sánchez Belda M
Correction. 10.1007/s12094-023-03183-9. 2023
Correction to: SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).
García-Campelo R; (...); Dómine M
Correction. 10.1007/s12094-023-03290-7. 2023
COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN
Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.
Meeting Abstract. 2024
Culprit-Lesion Drug-Coated-Balloon Percutaneous Coronary Intervention in Patients Presenting with ST-Elevation Myocardial Infarction (STEMI)
Sanz-Sanchez, Jorge; (...); Santos, Ignacio Amat
Article. 10.3390/jcm14030869. 2025
Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.
Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL
Editorial Material. 10.1016/j.farma.2024.08.001. 2024
Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study)
Aransay, N. Reguart; (...); Vila, A. Lloansi
Meeting Abstract. 10.1016/j.annonc.2023.09.2442. 2023
Chronological and Biological Age as a Response Factor to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
Suay, G.; (...); Juan-Vidal, O.
Meeting Abstract. 2024
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.
Ahn, Myung-Ju; (...); Sands, Jacob
Article. 10.1200/JCO-24-01544. 2024
Datopotamab Deruxtecan Vs Docetaxel in Patients with Non-Small Cell Lung Cancer: Final Overall Survival from TROPION-Lung01
Sands, J.; (...); Ahn, M-J
Meeting Abstract. 2024
Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.
Abad, Maria Reyes; (...); Gil, Alicia
Article. 10.33393/grhta.2024.3041. 2024
Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis
Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther
Article. 10.1002/jvc2.275. 2024
Development of a predictive model for early detection of lung cancer: SREAL-eLUNG study
Vidal, O. J. Juan; (...); Martinez, B. Valdivieso
Meeting Abstract. 2023
Does fractional flow reserve impact on clinical outcomes by reducing number of stents and contrast media? Findings from a systematic review (N = 56,185) and meta-analysis.
Teira Calderón A; (...); Garcia-Garcia HM
Letter. 10.1016/j.carrev.2023.12.010. 2024
Does Fractional Flow Reserve Impact on Clinical Outcomes? Findings From a Systematic Review (n=56,185) and Meta-Analysis
Teira Calderon, A.; (...); Garcia-Garcia, H. M.
Meeting Abstract. 2024
Dynamics and prognostic role of persistent angina in chronic coronary syndrome with clinical, angiographic and stress CMR evidence of ischemia
Merenciano-Gonzalez, H.; (...); Bodi, V
Meeting Abstract. 10.1093/eurheartj/ehae666.1329. 2024
ECONOMIC BURDEN OF ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS HARBORING KRASG12C MUTATION IN SPAIN
Fernandez-Barcelo, C.; (...); Sampietro-Colom, L.
Meeting Abstract. 2023
Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-METexon 14 skipping mutations (METex14).
Brandao, Mariana da Rocha Almeida; (...); Felip, Enriqueta
Meeting Abstract. 2024
Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study).
Marquez-Rodas, Ivan; (...); Berrocal, Alfonso
Article. 10.1093/neuonc/noae116. 2024
Endothelial Biomarkers Are Superior to Classic Inflammatory Biomarkers in Community-Acquired Pneumonia.
González-Jiménez P; (...); Méndez R
Article. 10.3390/biomedicines12102413. 2024
European Society of Medical Oncology (ESMO) guidelines for oncogene-addicted metastatic non-small cell lung cancer (NSCLC): a personalized treatment for each patient.
Suay, Guillermo, Aparisi, Francisco, Juan-Vidal, Oscar
Article. 10.21037/cco-23-100. 2024
Evaluation of EMBARK criteria patients. Real-world data on prostate cancer biochemical recurrence
Centelles Hidalgo, Elena; (...); Lopez-Campos, Fernando
Meeting Abstract. 2024
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer.
Arriola E; (...); Felip E
Article. 10.1007/s40261-024-01379-7. 2024
FAMetA: a mass isotopologue-based tool for the comprehensive analysis of fatty acid metabolism.
Alcoriza-Balaguer MI; (...); Lahoz A
Article. 10.1093/bib/bbad064. 2023
First-line (1L) nivolumab (N) plus ipilimumab (I) plus chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS)
Carbone, David Paul; (...); Reck, Martin
Meeting Abstract. 2023
First-line (1L) nivolumab (N) plus ipilimumab (I) plus chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS).
Carbone, David Paul; (...); Reck, Martin
Meeting Abstract. 10.1200/JCO.2023.41.17_suppl.LBA9023. 2023
First-line Nivolumab (N) plus Ipilimumab (I) plus Chemotherapy (C) in Metastatic NSCLC (mNSCLC): CheckMate 9LA 4-Year Clinical Update
Baclin, Firas; (...); Reck, Martin
Meeting Abstract. 2024
Five-year outcomes with first-line (1L) nivolumab plus ipilimumab plus chemotherapy (N plus I plus C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.
Reck, Martin; (...); Paz-Ares, Luis G.
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.8560. 2024
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial.
Reck M; (...); Paz-Ares LG
Article. 10.1016/j.ejca.2024.114296. 2024
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Carbone DP; (...); Reck M
Article. 10.1136/jitc-2023-008189. 2024
FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002)
Le, Xiuning; (...); Wang, Jie
Meeting Abstract. https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS8666. 2024
FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations
Le, X.; (...); Wang, J.
Meeting Abstract. 2024
GALLANT-1: GB1211 galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC)
Aparisi Aparisi, F. D. A.; (...); Ghiringhelli, F.
Meeting Abstract. 10.1016/j.annonc.2023.09.2491. 2023
Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.
Plaza J; (...); Moret-Tatay I
Article. 10.3390/ijms25073717. 2024
Genotypic Characteristics and Resistance Mutations in Advanced ALK plus NSCLC: The ALK-PATHFINDER Study
Lopez Castro, R.; (...); Ponce Aix, S.
Meeting Abstract. 2023
Health-Related Quality of Life (HRQoL) Outcomes with Adagrasib vs Docetaxel in KRASG12C-Mutated Advanced NSCLC in KRYSTAL-12
Felip, E.; (...); Duruisseaux, M.
Meeting Abstract. https://doi.org/10.1016/j.jtho.2024.09.056. 2024
How can artificial intelligence optimize value-based contracting?
Poveda, Jose Luis; (...); Medrano, Ignacio H.
Letter. 10.1186/s40545-022-00475-3. 2022
Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations
Suay, Guillermo; (...); Lahoz, Agustin
Review. 10.1016/j.canlet.2024.217317. 2024
Immunogenicity of COVID-19 vaccines in lung cancer patients.
Provencio M; (...); Calvo V
Article. 10.1016/j.lungcan.2023.107323. 2023
Impact of Advanced Age on the Incidence of Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stable Coronary Artery Disease in a Real-World Setting in Spain.
González-Juanatey C; (...); Savana Research Group
Article. 10.3390/jcm12165218. 2023
Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare Hospital.
Simarro, Javier; (...); Palanca, Sarai
Article. 10.3390/cancers15061705. 2023
Impact on Survival of Heart and Heart-Lung Transplantation in Patients With Cyanotic and Noncyanotic Congenital Heart Diseases.
Donoso-Trenado, Victor; (...); Almenar-bonet, Luis
Article. 10.1016/j.transproceed.2024.12.005. 2024
Initial and Residual Cardiovascular Damage Remaining at Day 30 in Community-acquired Pneumonia
Ocana, R. Mendez; (...); Menendez, R.
Meeting Abstract. https://doi.org/10.1164/ajrccm-conference.2024.209.1_MeetingAbstracts.A6241. 2024
Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.
Pozo-Rosich P; (...); Irimia P
Article. 10.1186/s10194-024-01747-w. 2024
Is the Benefit of Treating Iron Deficiency Greater in Acute Heart Failure with Renal Dysfunction?
Lopez-Vilella, Raquel; (...); Almenar Bonet L
Article. 10.3390/life13040915. 2023
Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.
Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula
Article. 10.3390/antibiotics13080706. 2024
KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation
Mok, Tony S. K.; (...); Barlesi, Fabrice
Meeting Abstract. 10.1200/JCO.2024.42.17_suppl.LBA8509. 2024
LATTICE radiotherapy: A one institution experience
Solero, I.; (...); Conde, A.
Meeting Abstract. 2023
Left bundle branch pacing versus left ventricular septal pacing as a primary procedural endpoint during left bundle branch area pacing: Evaluation of two different implant strategies.
Cano, Oscar; (...); Martinez-Dolz, Luis
Article. 10.1111/jce.16128. 2023
Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.
Vázquez Polo A; (...); Vázquez Costa JF
Article. 10.20960/nh.03946. 2022
Mortality after the first hospital admission for acute heart failure de novo vs. acutely decompensated heart failure with reduced ejection fraction
Lopez Vilella, R. Raquel; (...); Almenar Bonet, L.
Meeting Abstract. 2023
Mortality After the First Hospital Admission for Acute Heart Failure, De Novo Versus Acutely Decompensated Heart Failure With Reduced Ejection Fraction.
Lopez-Vilella, Raquel; (...); Almenar Bonet, Luis
Article. 10.1016/j.amjcard.2023.03.008. 2023
Multi-Institutional Analysis of Metastasis Directed Therapy with or without Androgen Deprivation Therapy in Oligometastatic Castration Sensitive Prostate Cancer.
Sutera, P.; (...); Sweeney, C.
Article. 10.1016/j.ijrobp.2023.06.1620. 2023
Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer.
Deek MP; (...); Sweeney C
Article. 10.1016/j.euo.2024.03.010. 2024
National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies
Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis
Meeting Abstract. 10.1182/blood-2022-169938. 2022
New challenges of advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2023.11.008. 2024
Node Oligorecurrence in Prostate Cancer: A Challenge.
Zapatero A; (...); Aldave D
Article. 10.3390/cancers15164159. 2023
Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small-Cell Lung Cancer: The Phase II BALTIC Study.
Reinmuth, Niels; (...); Bondarenko, Igor
Article. 10.1158/1078-0432.CCR-24-0013. 2024
Novel Fibrillar and Non-Fibrillar Collagens Involved in Fibrotic Scar Formation after Myocardial Infarction
Ortega, Maria; (...); Ruiz-Sauri, Amparo
Article. 10.3390/ijms25126625. 2024
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis
Article. 10.1097/MD.0000000000032208. 2022
ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.
Poveda JL; (...); Badia X
Article. 10.1186/s13023-022-02610-4. 2023
Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Review. 10.3390/biology12091159. 2023
OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT
Flores-Moreno, S.; (...); Gil, A.
Meeting Abstract. 2024
Oxygen therapy at 1.4 atmospheres in radiation-induced cystitis and proctitis
Prato Carreno, O. A.; (...); Conde Moreno, A. J.
Meeting Abstract. 2023
PEACE V-Salvage Treatment of oligorecurrent nodal prostate cancer metastases (STORM): 24-months toxicity results of a randomized phase II trial
Zilli, T.; (...); Ost, P.
Meeting Abstract. 2024
PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial.
Ost, Piet; (...); Zilli, Thomas
Article. 10.1016/j.euo.2023.09.007. 2023
Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives.
Cabrera-Romero E; (...); Garcia-Pavia P
Article. 10.1016/j.jacc.2024.02.036. 2024
Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.
Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis
Article. 10.3390/ijms26041760. 2025
Pharmacological Considerations during Percutaneous Treatment of Heart Failure.
Sorolla-Romero JA; (...); Sanz-Sanchez j
Article. 10.2174/0113816128284131240209113009. 2024
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05).
Nadal E; (...); Bruna J
Article. 10.1200/JCO.22.02561. 2023
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer.
Ahn, Myung-Ju; (...); Paz-Ares, Luis
Article. 10.1080/14796694.2024.2402152. 2024
Plaque modification and impact on the microcirculation territory after drug-coated balloon angioplasty. The PLAMI study design
Romero, Jose Antonio Sorolla; (...); Sanchez, Jorge Sanz
Article. 10.24875/RECIC.M23000438. 2024
Plasma fibroblast activation protein is decreased in acute heart failure despite cardiac tissue upregulation
Delgado-Arija, Marta; (...); Rosello-Lleti, Esther
Article. 10.1186/s12967-024-04900-w. 2024
Practical Requirements for the Development of an Advanced Cardiorenal Unit
Almenar-Bonet, Luis; (...); Sanchez-Perez, Pilar
Review. 10.1159/000536104. 2024
Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Poveda Andrés JL, Edo Solsona MD
Article. 10.1016/j.farma.2023.06.0131130. 2024
Prognostic role of persistent angina after percutaneous revascularization in chronic coronary syndrome with altered angiography and stress CMR.
Perez-Sole, Nerea; (...); Bodi, Vicente
Article. 10.1016/j.rec.2024.09.004. 2024
Pulmonary arterial hypertension associated with pretricuspid shunts: risk profile and survival.
Calvo-Asensio, Maria; (...); Rueda Soriano, Joaquin
Article. 10.1016/j.rec.2024.04.016. 2024
Radiation therapy for vulvar cancer: consensus guidelines of the GINECOR working group of the Spanish Society of Radiation Oncology. Part 1: clinical recommendations.
Cordoba Largo S; (...); Sánchez Belda M
Article. 10.1007/s12094-023-03095-8. 2023
Radiation therapy for vulvar cancer: consensus technical guidelines of the GINECOR working group of the Spanish Society of Radiation Oncology. Part 2: radiotherapy recommendations.
Cordoba Largo, Sofia; (...); Sanchez Belda M
Article. 10.1007/s12094-023-03101-z. 2023
Real-world evidence analysis of early-stage prostate cancer using natural language processing
Juarez, Alvaro; (...); Alcaraz, Antonio
Meeting Abstract. 2023
Real-world outcomes of first-line pembrolizumab (Pem) for metastatic non-small cell lung cancer (mNSCLC) with >= 50% expression of programmed cell death-ligand 1 (PD-L1): A multicentre retrospective study
Perea, J.; (...); Gaudens, P. Capdevila
Meeting Abstract. 2023
Re-irradiation in NSCLC High-dose RT: Control, Survival and Toxicity
Germain, J.; (...); Conde, A.
Meeting Abstract. 2023
RET Fusion Testing in Patients With NSCLC: The RETING Study.
Conde, Esther; (...); Lopez-Rios, Fernando
Article. 10.1016/j.jtocrr.2024.100653. 2024
RT after Encorafenib and Binimetinib on BRAF mutated melanoma brain metastases. GEM1802-Phase II
Alvarez, A.; (...); Marquez Rodas, I.
Meeting Abstract. 2023
Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.
Paz-Ares, Luis G.; (...); Garassino, Marina Chiara
Meeting Abstract. 10.1200/JCO.2024.42.17_suppl.LBA8500. 2024
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.
Paz-Ares, Luis G.; (...); Garassino, Marina Chiara
Article. 10.1200/JCO.24.00733. 2024
Sacituzumab Govitecan vs Docetaxel in Patients with mNSCLC Non-responsive to Last Anti-PD-(L)1containing Regimen: EVOKE-01
Garassino, M. C.; (...); Paz-Ares, L. G.
Meeting Abstract. 2024
Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM)
Ost, Piet; (...); Moon, Daniel
Meeting Abstract. 2024
SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).
Garcia-Campelo, Rosario; (...); Domine, Manuel
Article. 10.1007/s12094-023-03216-3. 2023
Sex and clinical outcomes in new-onset heart failure.
Vicent, Lourdes; (...); Martinez-Selles, Manuel
Article. 10.1016/j.ijcard.2025.133092. 2025
Sex Differences in the Efficacy of Immune Checkpoint Inhibitors in Neoadjuvant Therapy of Non-Small Cell Lung Cancer: A Meta-Analysis
Suay, Guillermo; (...); Juan-Vidal, Oscar
Review. 10.3390/cancers15184433. 2023
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer.
Peressini M; (...); Zugazagoitia J
Article. 10.1158/1078-0432.CCR-24-0104. 2024
Survival outcomes in ALK-positive NSCLC patients (p) treated 1st line brigatinib and impact of the ALK fusion variant
Provencio-Pulla, Mariano; (...); Romero, Atocha
Meeting Abstract. 2023
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
Ahn MJ; (...); Paz-Ares L
Article. 10.1056/NEJMoa2307980. 2023
The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity
Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar
Article. 10.1007/s00431-022-04628-z. 2022
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
Gomez Rueda, Ana; (...); Garrido, Pilar
Article. 10.1007/s12094-024-03404-9. 2024
The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Badia, Xavier; (...); Valles, Joan-Antoni
Article. 10.1186/s13023-024-03324-5. 2024
Therapeutic approach in heart failure with poor diuretic response. Peripheral ultrafiltration vs. conventional treatment
Lopez-Vilella, R.; (...); Almenar Bonet, L.
Meeting Abstract. 2023
Therapeutic approach in heart failure with poor diuretic response: peripheral ultrafiltration vs. conventional treatment.
López-Vilella R; (...); Almenar Bonet L
Article. 10.1002/ehf2.14386. 2023
Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.
Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis
Article. 10.1136/ejhpharm-2024-004184. 2024
Usefulness of biomarkers to predict prognosis after heart transplant
Lopez-Vilella, Raquel; (...); Boneta, Luis Almenar
Article. 10.1016/j.rec.2024.04.019. 2024
VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA
Poveda, J. L.; (...); Lizan, L.
Meeting Abstract. 2023